Market capitalization | $27.69m |
Enterprise Value | $39.26m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 59.48 |
P/S ratio (TTM) P/S ratio | 41.95 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -96.97% |
Revenue (TTM) Revenue | $660.00k |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Orgenesis Inc.:
1 Analyst has issued a forecast Orgenesis Inc.:
Jun '24 |
+/-
%
|
||
Revenue | 0.66 0.66 |
98%
98%
|
|
Gross Profit | -1.77 -1.77 |
106%
106%
|
|
EBITDA | -19 -19 |
384%
384%
|
EBIT (Operating Income) EBIT | -20 -20 |
235%
235%
|
Net Profit | -29 -29 |
111%
111%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment through MaSTherCell, comprises of services from cell therapy development through cell therapy manufacturing for and companies that provide end-to-end solution. The POC segment provides multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.
Head office | United States |
CEO | Vered Caplan |
Employees | 146 |
Founded | 2008 |
Website | www.orgenesis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.